cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aerovate Therapeutics Inc
1 watching
Current Price
$25.57
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
626.63M
52-Week High
52-Week High
30.79
52-Week Low
52-Week Low
8.33
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization626.63M
icon52-Week High30.79
icon52-Week Low8.33
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Aerovate Therapeutics Inc do?
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Aerovate Therapeutics Inc make?
News & Events about Aerovate Therapeutics Inc.
Zolmax
3days ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) CEO Timothy P. Noyes sold 15,000 shares of Aerovate Therapeutics stock in a transaction on Wednesday, February 1st. The stock was sold at an average price of $22.68, for a total transaction of $340,200.00. The sale was disclosed in a legal filing ...
Globe Newswire
17days ago
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as ...
Ticker Report
29days ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Benjamin T. Dake sold 10,284 shares of the businesss stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion ...
Zolmax
29days ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) insider Benjamin T. Dake sold 10,284 shares of the businesss stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion of the ...
Ticker Report
5 months ago
Aerovate Therapeutics, Inc. (NASDAQ:AVTE Get Rating) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,540,000 shares, an increase of 10.0% from the July 31st total of 1,400,000 shares. Based on an average...
Frequently Asked Questions
Frequently Asked Questions
What is Aerovate Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aerovate Therapeutics Inc shares?
plus_minus_icon
How can I buy Aerovate Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aerovate Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aerovate Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aerovate Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aerovate Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aerovate Therapeutics Inc?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aerovate Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$25.57
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00